ImmuCell Co. (NASDAQ:ICCC – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.95 and traded as low as $4.46. ImmuCell shares last traded at $4.49, with a volume of 873 shares traded.
ImmuCell Trading Down 7.4 %
The company has a market capitalization of $35.07 million, a price-to-earnings ratio of -8.80 and a beta of 0.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.00 and a current ratio of 2.71. The business’s 50-day simple moving average is $4.69 and its 200-day simple moving average is $4.95.
ImmuCell (NASDAQ:ICCC – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.06) earnings per share for the quarter. ImmuCell had a negative net margin of 18.31% and a negative return on equity of 15.21%. The business had revenue of $7.26 million during the quarter.
Hedge Funds Weigh In On ImmuCell
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
- Five stocks we like better than ImmuCell
- How to Capture the Benefits of Dividend Increases
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Why is the Ex-Dividend Date Significant to Investors?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.